Company: SION
Filing Date: 2025-02-03
Form Type: S-1/A
Source: 0001193125-25-018825
Chunk: 231

Company: Sionna Therapeutics, Inc.
Filing Date: 2025-02-03
Form: S-1/A
Chunk 231
---
directors of Kymera Therapeutics, Inc. (NASDAQ: KYMR) (“Kymera”), since March 2021 and Kronos Bio, Inc. (NASDAQ: KRON) since September 2020. Ms. Ridloff earned a B.A. in history and sociology of science from the University of
Pennsylvania and is a Chartered Financial Analyst.

Non-ExecutiveDirectors

Bruce Booth, D.Phil.,has served as a member of our board of directors since June 2020. Dr. Booth joined Atlas Venture in 2005
and currently serves as general partner. He also serves, or has previously served, as an advisor in various capacities to Takeda Pharmaceuticals Company Limited (NYSE: TAK), UCB Biopharmaceuticals and the Bill & Melinda Gates Foundation.
Dr. Booth co-founded Kymera and has served as chairman of its board of directors since April 2016. He has also served as chairman of Vigil Neuroscience, Inc. (NASDAQ: VIGIL) since June 2020.
Dr. Booth is chair or a member of the boards of directors of several private companies, including Nimbus Therapeutics, LLC, HotSpot Therapeutics, Inc., Arkuda Therapeutics, Inc. and Matchpoint Therapeutics, Inc. Dr. Booth previously served
on the boards of directors of AVROBIO, Inc. (now Tectonic Therapeutic, Inc. (NASDAQ: TECX)) from February 2016 to June 2024, Magenta Therapeutics, Inc. (now Dianthus Therapeutics, Inc. (NASDAQ: DNTH)) from February 2016 to September 2023 and Unum
Therapeutics, Inc. (now Cogent Biosciences, Inc. (NASDAQ: COGT)) from October 2014 to July 2020 and several private companies. Dr. Booth earned a B.S. in biochemistry, summa cum laude, from Pennsylvania State University. Dr. Booth was a
British Marshall Scholar and earned a D.Phil. in molecular immunology from Oxford University’s Nuffield Department of Medicine. We believe Dr. Booth’s extensive leadership, executive, managerial and business experience with life
sciences companies and experience as a public company board member provides him with the appropriate set of skills to serve as a member of our board of directors.

Paul Clancy, M.B.A.,has served as chair of our board of directors since June 2022. Mr